metricas
Archivos de la Sociedad Española de Oftalmología (English Edition) Associations of dose adjustment with efficacy and safety of faricimab for age-re...
Journal Information
Vol. 101. Issue 8.
(August 2026)
Cite
Cite
Share
Download PDF
More article options
Visits
690
Vol. 101. Issue 8.
(August 2026)
Review

Associations of dose adjustment with efficacy and safety of faricimab for age-related macular degeneration disorders: A systematic review and meta-analysis

Asociaciones del ajuste de dosis con la eficacia y seguridad de faricimab para los trastornos de degeneración macular relacionados con la edad: una revisión sistemática y metanálisis
Visits
690
B. Benedictusa, S.T. Alaydrusa,
Corresponding author
syechaalaydrus@gmail.com

Corresponding author.
, H.K. Ronikb, Y.A. Dwinastitic, B. Priscillac, E. Novaa
a Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia
b Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
c Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract

This paper reviews the efficacy and safety of various dosing regimens and treatment cycles of intravitreal faricimab as therapy for Age-related macular degeneration (ARMD). The included studies were randomized controlled trials (RCTs) or post-hoc analyses of RCTs involving a population of ARMD or macular related disorder patients receiving faricimab therapy. Study outcomes were assessed by best-corrected visual acuity (BCVA) or central macular subfield thickness (CST). Data extracted from the journals included characteristics of the patient population, subgroup population, treatment used, therapeutic dose, treatment cycle, BCVA, CVA, number of populations with severe adverse events, and severe ocular adverse events. Study heterogeneity was assessed using the I² statistic, with values ≤ 40% considered homogeneous. A random effects model was applied when effect estimates crossed the line of no effect. Effect sizes were reported as mean differences with 95% confidence intervals. We included eight studies with a total of 8458 study populations. There are several doses that can be given (1.5 mg and 6 mg) and several cycles of administration (every 4, 8, 12, 16 weeks and personalized treatment interval). Faricimab 6 mg every sixteen weeks has shown a better effect than aflibercept and ranibizumab. These findings suggest that faricimab 6 mg administered every sixteen weeks demonstrated superior outcomes in improving best-corrected visual acuity (BCVA) and greater reductions in central subfield thickness (CST) compared to aflibercept 2 mg every eight weeks. However, a more frequent regimens were associated with significantly higher severe adverse events, especially ocular severe adverse events.

Keywords:
Faricimab
Intravitreal
Age-related macular degeneration
Best corrected visual acuity
Central macular subfield thickness
Resumen

Este artículo evalúa la eficacia y seguridad de diferentes pautas posológicas y ciclos de tratamiento con faricimab intravítreo para la degeneración macular asociada a la edad (DMAE). Los estudios incluidos fueron ensayos controlados aleatorios (ECA) o análisis post hoc de ECA que incluyeron una población de pacientes con DMAE o trastornos maculares relacionados que recibían tratamiento con faricimab. Los resultados se midieron mediante la agudeza visual mejor corregida (AVMC) y el grosor del subcampo central (GSC). Los datos extraídos incluyeron características poblacionales, subgrupos, fármaco utilizado, dosis, intervalo de tratamiento, AVMC, GSC, número de pacientes con eventos adversos graves y eventos adversos oculares. La heterogeneidad se evaluó con el estadístico I², considerando homogéneos los valores ≤ 40%. Se utilizó un modelo de efectos aleatorios cuando las estimaciones del efecto cruzaban la línea de nulidad. La magnitud del efecto se expresó como diferencias de medias con intervalos de confianza del 95%. Se incluyeron ocho estudios con un total de 8458 participantes. Se evaluaron distintas dosis (1,5 mg y 6 mg) y ciclos de administración (cada 4, 8, 12 y 16 semanas, incluyendo esquemas personalizados). El faricimab 6 mg cada 16 semanas demostró mejores resultados que aflibercept y ranibizumab. Estos hallazgos sugieren que faricimab 6 mg cada 16 semanas logra mayores mejoras en la AVMC y mayores reducciones en el GSC en comparación con aflibercept 2 mg cada 8 semanas. Sin embargo, los esquemas más frecuentes se asociaron con un aumento significativo de eventos adversos graves, especialmente oculares.

Palabras clave:
Faricimab
Intravítreo
Degeneración macular relacionada con la edad
Agudeza visual corregida
Grosor del subcampo macular central

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
References
[1]
J.H. Tan, S.V. Bhandary, S. Sivaprasad, et al.
Age-related Macular Degeneration detection using deep convolutional neural network.
Future Gener Comput Syst, 87 (2018), pp. 127-135
[2]
C.N. Thomas, D.A. Sim, W.H. Lee, et al.
Emerging therapies and their delivery for treating age‐related macular degeneration.
Br J Pharmacol, 179 (2022), pp. 1908-1937
[3]
M.E. Hartnett, J.J. Weiter, G. Staurenghi, A.E. Elsner.
Deep retinal vascular anomalous complexes in advanced age-related macular degeneration.
Ophthalmology, 103 (1996), pp. 2042-2053
[4]
N.M. Bressler.
Age-related macular degeneration is the leading cause of blindness.
[5]
H. Nazimul, K. Rohit, H. Anjli.
Trend of retinal diseases in developing countries.
Exp Rev Ophthalmol, 3 (2008), pp. 43-50
[6]
P.A. Campochiaro.
Retinal and choroidal vascular diseases: past, present, and future: the 2021 proctor lecture.
Invest Ophthalmol Vis Sci, 62 (2021), pp. 26
[7]
S.R. Flaxman, R.R.A. Bourne, S. Resnikoff, et al.
Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis.
Lancet Global Health, 5 (2017), pp. e1221-e1234
[8]
B. Jiang, C. Jiang, J. Li, P. Lu.
Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: results from the global burden of disease study 2019.
Front Public Health, 11 (2023),
[9]
Y. Deng, L. Qiao, M. Du, et al.
Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy.
[10]
J.Q. Li, T. Welchowski, M. Schmid, M.M. Mauschitz, F.G. Holz, R.P. Finger.
Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis.
Br J Ophthalmol, 104 (2020), pp. 1077-1084
[11]
E.S. Tai.
Prevalence of and risk factors for age-related macular degeneration in a multiethnic Asian cohort.
Arch Ophthalmol, 130 (2012), pp. 480
[12]
J. Chuan, L. Liu, Y. Feng, M. Wang, G. Li, Q. Lv.
The efficacy and safety of brolucizumab for the treatment of nAMD: a systematic review and meta-analysis.
[13]
H. Vyawahare, P. Shinde.
Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment.
[14]
M.J. Page, J.E. McKenzie, P.M. Bossuyt, et al.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
BMJ, 372 (2021), pp. n71
[15]
J.A.C. Sterne, J. Savović, M.J. Page, et al.
RoB 2: a revised tool for assessing risk of bias in randomised trials.
[16]
J.S. Heier, A.M. Khanani, C. Quezada Ruiz, et al.
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
[17]
K. Takahashi, C.M.G. Cheung, T. Iida, et al.
Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-year subgroup analysis of the TENAYA and LUCERNE trials.
Graefes Arch Clin Exp Ophthalmol, 261 (2023), pp. 3125-3137
[18]
R. Mori, S. Honda, F. Gomi, et al.
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Jpn J Ophthalmol, 67 (2023), pp. 301-310
[19]
J. Sahni, P.U. Dugel, S.S. Patel, et al.
Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial.
JAMA Ophthalmol, 138 (2020), pp. 955
[20]
A.M. Khanani, S.S. Patel, P.J. Ferrone, et al.
Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial.
JAMA Ophthalmol, 138 (2020), pp. 964
[21]
M. Shimura, S. Kitano, N. Ogata, et al.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Jpn J Ophthalmol, 67 (2023), pp. 264-279
[22]
J. Sahni, S.S. Patel, P.U. Dugel, et al.
Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema.
Ophthalmology, 126 (2019), pp. 1155-1170
[23]
S. Ishida, S.J. Chen, T. Murata, et al.
Efficacy, durability, and safety of faricimab in patients from Asian countries with diabetic macular edema: 1-year subgroup analysis of the phase III YOSEMITE and RHINE trials.
Asia Pac J Ophthalmol (Phila), 12 (2023), pp. 451-459
[24]
H. Agostini, F. Abreu, C.R. Baumal, et al.
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
Graefes Arch Clin Exp Ophthalmol, 262 (2024), pp. 3437-3451
[25]
V. Chaudhary, F. Mar, M.J. Amador, et al.
Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases.
Graefes Arch Clin Exp Ophthalmol, 263 (2025), pp. 1239-1247
[26]
C. Diack, R.L. Avery, C.M.G. Cheung, et al.
Ocular pharmacodynamics of intravitreal faricimab in patients with neovascular age-related macular degeneration or diabetic macular edema.
Trans Vis Sci Tech, 13 (2024), pp. 13
[27]
N. Eter, R.P. Singh, F. Abreu, et al.
YOSEMITE and RHINE.
[28]
R.M. Hussain, P. O’Leary, D.A. Eichenbaum, S.M. Hariprasad.
Faricimab. Anti-Ang-2/anti-VEGF-A bispecific antibody, treatment of diabetic macular edema, treatment of wet age-related macular degeneration.
Drugs Future, 45 (2020), pp. 449
[29]
G.Y. Koh, H.G. Augustin, P.A. Campochiaro.
Viewpoints: dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye.
Trends Mol Med, 28 (2022), pp. 347-349
[30]
S. Vujosevic, M. Lupidi, S. Donati, C. Astarita, V. Gallinaro, E. Pilotto.
Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration.
Surv Ophthalmol, 69 (2024), pp. 870-881
[31]
T.Y. Wong, Z. Haskova, K. Asik, et al.
Faricimab treat-and-extend for diabetic macular edema.
Ophthalmology, 131 (2024), pp. 708-723
[32]
A.V. Zolotarev, E.V. Karlova, E.V. Balandina, et al.
Dual inhibition of VEGF-A and angiopoietin-2 in the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Rus Ann Ophthal, 140 (2024), pp. 100
[33]
S. Inoda, H. Takahashi, R. Takahashi, et al.
Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular age-related macular degeneration in patients with prior treatment history.
Ophthalmol Ther, 12 (2023), pp. 2703-2712
[34]
C. Diack, L. Gibiansky, F. Jaminion, et al.
Ocular pharmacokinetics of faricimab following intravitreal administration in patients with retinal disease.
Trans Vis Sci Tech, 13 (2024), pp. 14
[35]
M. Takeuchi, T. Sato, Y. Sakurai, et al.
Association between aqueous humor and vitreous fluid levels of Th17 cell-related cytokines in patients with proliferative diabetic retinopathy.
[36]
A. Mashima, H. Noma, K. Yasuda, H. Goto, M. Shimura.
Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion.
[37]
Y. Zhang, Z. Gao, X. Zhang, et al.
Effect of intravitreal conbercept injection on VEGF‑A and ‑B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy.
Exp Ther Med, 21 (2021), pp. 332
[38]
E. Strobbe, M. Cellini, M. Fresina, E.C. Campos.
ET-1 plasma levels, aqueous flare, and choroidal thickness in patients with retinitis pigmentosa.
J Ophthalmol, 2015 (2015), pp. 1-6
[39]
S. Ueki, Y. Suzuki, H. Igarashi.
Retinal Aquaporin-4 and regulation of water inflow into the vitreous body.
Invest Ophthalmol Vis Sci, 62 (2021), pp. 24
[40]
N. Dong, B. Xu, L. Chu, X. Tang.
Study of 27 aqueous humor cytokines in type 2 diabetic patients with or without macular edema.
[41]
N. Kongyai, K. Pathanapitoon, W. Sirirungsi, P. Kunavisarut, J.D.F. De Groot-Mijnes, A. Rothova.
Infectious causes of posterior uveitis and panuveitis in Thailand.
Jpn J Ophthalmol, 56 (2012), pp. 390-395
[42]
H. Matsubara, R. Nagashima, S. Chujo, et al.
Subclinical ocular changes after intravitreal injections of different anti-VEGF agents for neovascular age-related macular degeneration.
J Clin Med, 12 (2023), pp. 7401
[43]
S. Wang, Z. Wang, S. Yang, et al.
Tissue distribution of trans-resveratrol and its metabolites after oral administration in human eyes.
J Ophthalmol, 2017 (2017), pp. 1-12
[44]
Y. Orii, E. Kunikane, Y. Yamada, et al.
Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: an interventional study.
[45]
K. Fujiwara, Y. Ikeda, Y. Murakami, et al.
Association between aqueous flare and epiretinal membrane in retinitis pigmentosa.
Invest Ophthalmol Vis Sci, 57 (2016), pp. 4282
[46]
J. Beirão, V. Miranda, B. Pinheiro-Torres, J. Coelho, M.J. Menéres, P. Menéres.
Anterior chamber flare as an objective and quantitative noninvasive method for oculopathy in transthyretin V30M amyloidosis patients.
J Ophthalmol, 2018 (2018), pp. 1-5
[47]
H. Suk-Gyu, B. Kang, J.S. Song.
Increased angiogenic factors in the aqueous and vitreous humors after disinsertion of extraocular muscle and the effects of triamcinolone acetate injection.
[48]
M. Mimura, T. Akagi, R. Kohmoto, Y. Fujita, Y. Sato, T. Ikeda.
Measurement of vitreous humor pressure in vivo using an optic fiber pressure sensor.
[49]
K. Mochizuki, S. Suemori, K. Udo, et al.
Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis.
J Ocular Pharmacol Ther, 27 (2011), pp. 531-533
[50]
F. Pichi, A. Abdi, S. Aljneibi, I. El Ghrably, A. Agarwal, N.G. Ghazi.
Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema.
Int Ophthalmol, 44 (2024), pp. 275
[51]
N. Leveziel, T. Pelat, H. Watier, P. Thullier, E.H. Souied.
Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration.
Ophthalmologica, 232 (2014), pp. 53-56
[52]
P. Arendt, S. Yu, M.R. Munk, A. Ebneter, S. Wolf, M.S. Zinkernagel.
EXIT strategy in a treat-and-extend regimen for exudative age-related macular degeneration.
[53]
M. Cozzi, A. Ziegler, K. Fasler, D.R. Muth, F. Blaser, S.A. Zweifel.
Sterile intraocular inflammation associated with faricimab.
JAMA Ophthalmol, 142 (2024), pp. 1028
[54]
E.H. Leung, D.J. Oh, S.E. Alderson, et al.
Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration.
Clin Ophthalmol, 17 (2023), pp. 1287-1293
[55]
H. Koizumi, F. Gomi, A. Tsujikawa, et al.
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.
Graefes Arch Clin Exp Ophthalmol, 262 (2024), pp. 2439-2448
[56]
T. Hirano, Y. Toriyama, Y. Takamura, et al.
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema.
[57]
D.T. Wong, S. Aboobaker, D. Maberley, S. Sharma, P. Yoganathan.
Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations.
[58]
J. Canonica, R. Foxton, M.G. Garrido, et al.
Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion.
Front Cell Neurosci, 17 (2023),
[59]
M. Pombo-Suarez, J.R. Maneiro Fernandez, J.J. Gomez-Reino.
Adherence to treatment in patients with rheumatoid arthritis from Spain.
Patient Prefer Adherence, 15 (2021), pp. 111-117
[60]
J. Montero Hernández, L. Remolí Sargues, C. Monferrer Adsuara, V. Castro Navarro, C. Navarro Palop, E. Cervera Taulet.
Two-year results of a treat and extend regimen with aflibercept in Caucasian patients with aneurysmal type 1 neovascularization.
Eur J Ophthalmol, 32 (2022), pp. 377-384
[61]
S.V. Savant.
Durability and efficacy of faricimab in treatment-resistant retinal edema utilizing “real-world” dosing regimens.
J Ophthalmol, 2024 (2024),
[62]
S.V. Savant, J.T. Kwan, F. Barouch, et al.
Durability and Efficacy of faricimab in treatment‐resistant retinal edema utilizing “real‐world” dosing regimens.
J Ophthalmol, 2024 (2024),
[63]
H. Takahashi, S. Inoda, H. Takahashi, et al.
One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment.
[64]
N. Quah, K.M.A.A. Javed, L. Arbi, D. Hanumunthadu.
Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema.
Clin Ophthalmol, 18 (2024), pp. 1479-1490
[65]
L. Toto, F. Formenti, M.L. Ruggeri, et al.
Efficacy and durability of faricimab in naïve eyes with neovascular age-related macular degeneration.
Ophthalmic Res, 67 (2024), pp. 528-536
asdasdasd
Article options
Tools